Kala Pharmaceuticals Announces $22.5 Million Series B Financing

por Ysios Capital

Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform technology, today announced it has comp...

Leer más
Subscribirse al Directorio
Escribir un Artículo

Destacadas

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology

tuTECHÔ se convierte en la primera empr...

by EY - Ernst & Young

tuTECHÔ, empresa social que lucha contra el sinhogarismo en España, ...

Diapositiva de Fotos